TACSTD2 and colonic neoplasm: A Trop2-focused nanobody–drug conjugate has already shown potent antitumor activity in pancreatic-cancer xenografts [48], and iterative bio-panning has yielded additional nanobodies, including the sequence on which our NB60 clone is based, that suppress proliferation and migration of Trop2-positive colon-cancer cells [49].